Want to see RGEN full AI Analyst Report?
RGEN Stock Chart & Stats
$180.30
-$5.64(-4.10%)
At close: 4:00 PM EDT
$180.30
-$5.64(-4.10%)
Day’s Range― - ―
52-Week Range$100.99 - $198.87
Previous CloseN/A
Volume1.36M
Average Volume (3M)1.21M
Market Cap
$11.36B
Enterprise Value$7.61B
Total Cash (Recent Filing)$810.45M
Total Debt (Recent Filing)$690.94M
Price to Earnings (P/E)243.3
Beta1.38
Next Earnings
Oct 27, 2026EPS Estimate
0.46Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.74
Shares Outstanding63,490,364
10 Day Avg. Volume1,330,270
30 Day Avg. Volume1,208,562
Financial Highlights & Ratios
PEG Ratio-0.65
Price to Book (P/B)4.38
Price to Sales (P/S)12.48
P/FCF Ratio98.13
Enterprise Value/Market Cap0.67
Enterprise Value/Revenue9.69
Enterprise Value/Gross Profit18.98
Enterprise Value/Ebitda43.53
Forecast
1Y Price Target
$202.50Price Target Upside12.31% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)2.06
Revenue Forecast (FY)$828.75M
Bulls Say, Bears Say
Bulls Say
Recurring Organic GrowthBroad recurring revenue growth indicates durable customer demand across Repligen’s bioprocessing portfolio rather than reliance on a single product or event. Continued adoption supports repeat purchasing, improves visibility, and provides a foundation for sustained expansion as biologics manufacturing grows.
Strong Cash GenerationPositive operating cash flow and a substantial liquidity position strengthen Repligen’s ability to fund research, commercial expansion, acquisitions, and capital investment internally. This financial flexibility can support growth initiatives while reducing dependence on additional borrowing or equity issuance.
Cell Therapy ExpansionThe completed BioLife acquisition broadens Repligen’s exposure to cell therapy and adds recurring consumables to its product mix. Combining BioLife’s portfolio with Repligen’s global commercial reach may deepen customer relationships and create a larger platform for participation in emerging modalities.
Bears Say
Profitability Below Prior PeaksAlthough profitability has recovered, margins and returns remain materially below earlier peak levels, showing that earnings quality has not fully normalized. Lower returns on the existing asset and equity base could constrain internal compounding and leave results more sensitive to mix, volume, and execution.
Filtration And Regional HeadwindsWeak filtration performance and continued regional pressure create a meaningful offset to growth in Repligen’s core portfolio. If customer inventory management, delayed implementations, and program-specific demand issues persist, they could weigh on near-term revenue conversion and reduce operating leverage.
Moderate Leverage And Low ReturnsLeverage remains manageable, but the increase in debt alongside low shareholder returns reduces financial efficiency compared with the company’s stronger historical profile. Until earnings improve further, more capital is tied to financing obligations without generating commensurate returns for equity holders.
Repligen News
RGEN FAQ
What was Repligen Corp’s price range in the past 12 months?
Repligen Corp lowest stock price was $100.99 and its highest was $198.87 in the past 12 months.
What is Repligen Corp’s market cap?
Repligen Corp’s market cap is $11.36B.
When is Repligen Corp’s upcoming earnings report date?
Repligen Corp’s upcoming earnings report date is Oct 27, 2026 which is in 5 days.
How were Repligen Corp’s earnings last quarter?
Repligen Corp released its earnings results on Jul 28, 2026. The company reported $0.54 earnings per share for the quarter, beating the consensus estimate of $0.447 by $0.093.
Is Repligen Corp overvalued?
According to Wall Street analysts Repligen Corp’s price is currently Undervalued.
Does Repligen Corp pay dividends?
Repligen Corp does not currently pay dividends.
What is Repligen Corp’s EPS estimate?
Repligen Corp’s EPS estimate is 0.46.
How many shares outstanding does Repligen Corp have?
Repligen Corp has 63,490,364 shares outstanding.
What happened to Repligen Corp’s price movement after its last earnings report?
Repligen Corp reported an EPS of $0.54 in its last earnings report, beating expectations of $0.447. Following the earnings report the stock price went up 10.896%.
Which hedge fund is a major shareholder of Repligen Corp?
Currently, no hedge funds are holding shares in RGEN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Repligen Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$202.50 (12.31% Upside)
$202.50 (12.31% Upside)
Blogger Sentiment
Neutral
RGEN Sentiment 57%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Increased
By 713.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.9%
Last 30 Days ▲ 756.8%
Last 30 Days ▲ 756.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
14.83%
12-Months-Change
Fundamentals
Return on Equity
1.98%
Trailing 12-Months
Asset Growth
1.67%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Repligen Corp
Repligen Corporation specializes in the creation and distribution of advanced bioprocessing technologies and integrated systems. These solutions are vital for various stages of biological drug production, serving clients across North America, Europe, the Asia Pacific region, and other international markets. The company's diverse product portfolio includes crucial components for biomanufacturing. This encompasses Protein A ligands, which serve as the key binding elements within Protein A affinity chromatography resins, as well as specialized cell culture growth factors. In the realm of chromatography, Repligen offers a range of products: Its OPUS line features pre-packed chromatography columns, instrumental in purifying biologics, alongside smaller-scale OPUS columns designed for high-throughput process development screening, viral clearance validation studies, and the scaling-down of chromatography processes. Additionally, the company supplies ELISA test kits and chromatography resins marketed under the CaptivA brand. Repligen also boasts an extensive suite of filtration products. This includes XCell Alternating Tangential Flow systems, which are filtration devices utilized in upstream perfusion and cell culture processing. For downstream applications like biologic drug concentration and formulation, they provide TangenX flat sheet cassettes. Other filtration offerings encompass KrosFlo tangential flow filtration and tangential flow depth filtration systems, Spectra/Por laboratory and process dialysis products, SpectraFlo dynamic dialysis systems, and ProConnex single-use hollow fibers. Furthermore, Repligen addresses process analytics with its slope spectroscopy systems, branded as SoloVPE, FlowVPE, and FlowVPX. Their clientele is broad, consisting of life sciences organizations, biopharmaceutical and diagnostics companies, laboratory researchers, and contract manufacturing organizations. Repligen also collaborates with partners, such as Navigo Proteins GmbH, on the development of various affinity ligands. The corporation was founded in 1981 and maintains its corporate headquarters in Waltham, Massachusetts.
RGEN Company Deck
RGEN Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was strongly positive. Repligen reported 13% organic second-quarter growth, substantial margin expansion, strong performance in Proteins, Analytics, APAC, and emerging biotech, and raised its full-year revenue and EPS guidance. The company also highlighted improved order momentum, a growing 2027 capital equipment backlog, and the financially accretive BioLife acquisition. These positives outweighed the disclosed challenges in Filtration, EMEA, capital equipment revenue, tariffs, and expected third-quarter margin and expense dynamics.View all RGEN earnings summariesRGEN Revenue Breakdown
44.00% North America
37.00% Europe
19.00% APAC/Other
RGEN Stock 12 Month Forecast
Average Price Target
$202.50
▲(12.31% Upside)
Technical Analysis
Ownership Overview
0.60% Insiders
37.89% Mutual Funds
4.06% Other Institutional Investors
35.19% Public Companies and Individual Investors